Electromed (NYSEAMERICAN:ELMD) Rating Lowered to Sell at Zacks Investment Research

Electromed (NYSEAMERICAN:ELMD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest® Airway Clearance System and related products. The patented system uses High Frequency Chest Wall Oscillation (HFCWO), an alternative to Chest Physiotherapy (CPT), to deliver airway clearance treatment. The Company manufactures its products for use by chronically-ill patients who face health risks due to pneumonia and mucus accumulation in the lungs, particularly patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and neuro-muscular disorders. The purpose of its primary product, the SmartVest System, is to loosen, mobilize, and release respiratory secretions from the lungs. The Company’s products are primarily used in the home health care market and in hospitals. Electromed, Inc. is headquartered in New Prague, Minnesota. “

ELMD opened at $15.30 on Tuesday. Electromed has a fifty-two week low of $5.17 and a fifty-two week high of $19.73.

Electromed (NYSEAMERICAN:ELMD) last announced its quarterly earnings data on Tuesday, May 12th. The medical equipment provider reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. The company had revenue of $8.74 million during the quarter.

In other Electromed news, Director George H. Winn sold 10,000 shares of Electromed stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $15.34, for a total value of $153,400.00. Following the sale, the director now owns 143,088 shares of the company’s stock, valued at $2,194,969.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Hedge funds have recently made changes to their positions in the business. Hillsdale Investment Management Inc. purchased a new position in shares of Electromed in the first quarter worth about $26,000. Wells Fargo & Company MN purchased a new position in shares of Electromed in the first quarter worth about $48,000. Advisor Group Holdings Inc. purchased a new position in shares of Electromed in the first quarter worth about $78,000. Wedge Capital Management L L P NC purchased a new position in shares of Electromed in the first quarter worth about $132,000. Finally, Cavalier Investments LLC purchased a new position in shares of Electromed in the first quarter worth about $225,000.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products in the United States and internationally. The company offers SmartVest airway clearance system that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to patients with compromised pulmonary function; and SmartVest SQL System that provides advanced generator programmability and an enhanced pause feature with save, lock, and restore functionality.

Featured Story: How Do Mutual Funds Work?

Get a free copy of the Zacks research report on Electromed (ELMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Electromed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed and related companies with MarketBeat.com's FREE daily email newsletter.